share_log

Novavax | 8-K: Poll Results of 2024 Stockholders Meeting

Novavax | 8-K: Poll Results of 2024 Stockholders Meeting

諾瓦瓦克斯醫藥 | 8-K:2024年股東大會會議決議公告
美股SEC公告 ·  2024/06/14 16:07

Moomoo AI 已提取核心訊息

At Novavax's Annual Meeting on June 13, 2024, shareholders approved several key proposals, including an increase of 6.5 million shares to the 2015 Stock Incentive Plan and an expansion of the Employee Stock Purchase Plan by 1 million shares. The ESPP's total available shares will be the lesser of 2.15 million shares (with 5% annual increases) or 3.51 million shares.Stockholders re-elected three Class II directors - Richard H. Douglas, Margaret G. McGlynn, and David Mott - to serve three-year terms until 2027. The meeting also saw the approval of executive compensation in an advisory vote and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2024.The Annual Meeting had strong shareholder participation with 75.76 million shares represented by proxy out of 140.40 million outstanding shares, constituting a quorum for all matters voted upon.
At Novavax's Annual Meeting on June 13, 2024, shareholders approved several key proposals, including an increase of 6.5 million shares to the 2015 Stock Incentive Plan and an expansion of the Employee Stock Purchase Plan by 1 million shares. The ESPP's total available shares will be the lesser of 2.15 million shares (with 5% annual increases) or 3.51 million shares.Stockholders re-elected three Class II directors - Richard H. Douglas, Margaret G. McGlynn, and David Mott - to serve three-year terms until 2027. The meeting also saw the approval of executive compensation in an advisory vote and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2024.The Annual Meeting had strong shareholder participation with 75.76 million shares represented by proxy out of 140.40 million outstanding shares, constituting a quorum for all matters voted upon.
2024年6月13日,Novavax公司舉行年度股東大會,股東們對幾項關鍵提案進行了投票表決。股東批准修訂並重申2015年經修訂的股票激勵計劃,將增加可發行股票數量650萬股。此外,2013年職工購股計劃也經修訂並重申,可發行股票數量增加了100萬股。股東還選出三名二類董事來擔任爲期三年的任期,批准2023年的高級管理人員報酬,並覈准Ernst & Young LLP爲截至2024年12月31日的財年獨立註冊公共會計師事務所。這些提案的細節已經在2024年4月29日向SEC提交的代理聲明中詳述,並在2024年6月5日進行了修訂。修訂計劃的全文已被納入提交的8-K表格的展示部分。
2024年6月13日,Novavax公司舉行年度股東大會,股東們對幾項關鍵提案進行了投票表決。股東批准修訂並重申2015年經修訂的股票激勵計劃,將增加可發行股票數量650萬股。此外,2013年職工購股計劃也經修訂並重申,可發行股票數量增加了100萬股。股東還選出三名二類董事來擔任爲期三年的任期,批准2023年的高級管理人員報酬,並覈准Ernst & Young LLP爲截至2024年12月31日的財年獨立註冊公共會計師事務所。這些提案的細節已經在2024年4月29日向SEC提交的代理聲明中詳述,並在2024年6月5日進行了修訂。修訂計劃的全文已被納入提交的8-K表格的展示部分。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息